← Leaderboards

Miguel-Angel Perales

Sloan-Kettering Institute For Cancer Res

Google Scholar ↗PubMed ↗ORCID ↗

$7,415,804

Attributed

$10,148,443

Total exposure

8

Grants

6

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$10,148,443 · 8

By mechanism

R01$4,790,498 · 2

P01$2,900,920 · 4

UG1$1,918,537 · 1

K08$538,488 · 1

Top collaborators

Most similar at Sloan-Kettering Institute For Cancer Res

Same institution · by research overlap

Others in their field

Top investigators on “Toxic Effect”

George R Seage · Abt Associates, Inc.$224,114,540
Peter C Adamson · National Childhood Cancer Foundation$126,756,857
Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
Carol Nesel · Westat$116,355,411
Mary M Horowitz · Medical College Of Wisconsin$90,165,506
Barney Sparrow · Battelle Memorial Institute$88,494,220

Research focus

Toxic EffectAdultCellsInfusion ProceduresCytokineMemorial Sloan-Kettering Cancer CenterRelapseT-LymphocyteMalignant - DescriptorImmuneB-LymphocytesClinical TrialsRecurrent DiseaseCd19 GeneInfectionChimeric Antigen Receptor T CellsTransplantationDesignKineticsCell TherapyAdoptive ImmunotherapyHematopoietic Stem Cell TransplantationRecoveryRegimen

Grant awards (28)

Optimizing HCT Outcomes: A Multi-omic Investigation$2,024,340

R01 · FY2025 · HL

Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy$977,273

R01 · FY2025 · CA

BMT Core - MSK$264,000

UG1 · FY2025 · HL · contact PI

Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy$858,502

R01 · FY2024 · CA

BMT Core - MSK$264,000

UG1 · FY2024 · HL · contact PI

Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy$930,383

R01 · FY2023 · CA

Core C: Special Assessment of Graft Function Post Transplant$267,354

P01 · FY2023 · CA · contact PI

MSKCC BMT CTN Renewal$194,309

UG1 · FY2023 · HL · contact PI

Core C: Special Assessment of Graft Function Post Transplant$258,336

P01 · FY2022 · CA · contact PI

MSKCC BMT CTN Renewal$197,052

UG1 · FY2022 · HL · contact PI

Core C: Special Assessment of Graft Function Post Transplant$266,851

P01 · FY2021 · CA · contact PI

MSKCC BMT CTN Renewal$200,089

UG1 · FY2021 · HL · contact PI

Core C: Special Assessment of Graft Function Post Transplant$267,354

P01 · FY2020 · CA · contact PI

MSKCC BMT CTN Renewal$204,275

UG1 · FY2020 · HL · contact PI

Core C: Special Assessment of Graft Function Post Transplant$8,561

P01 · FY2020 · CA · contact PI

Core C: Special Assessment of Graft Function Post Transplant$267,354

P01 · FY2019 · CA · contact PI

MSKCC BMT CTN Renewal$208,408

UG1 · FY2019 · HL · contact PI

MSKCC BMT CTN Renewal$192,604

UG1 · FY2018 · HL · contact PI

Graft Characterization and Monitoring of Immune Hematopoietic Reconstitution$288,923

P01 · FY2017 · CA · contact PI

MSKCC BMT CTN Renewal$193,800

UG1 · FY2017 · HL · contact PI

Graft Characterization and Monitoring of Immune Hematopoietic Reconstitution$321,458

P01 · FY2016 · CA · contact PI

Graft Characterization and Monitoring of Immune Hematopoietic Reconstitution$321,458

P01 · FY2015 · CA · contact PI

Graft Characterization and Monitoring of Immune Hematopoietic Reconstitution$311,813

P01 · FY2014 · CA · contact PI

Graft Characterization and Monitoring of Immune Hematopoietic Reconstitution$321,458

P01 · FY2013 · CA · contact PI

Optimizing T cell Immunity to Cancer Vaccines$134,703

K08 · FY2006 · CA · contact PI

Optimizing T cell Immunity to Cancer Vaccines$134,703

K08 · FY2005 · CA

Optimizing T cell Immunity to Cancer Vaccines$134,703

K08 · FY2004 · CA

Optimizing T cell Immunity to Cancer Vaccines$134,379

K08 · FY2003 · CA